Table 1.
Clinical features of KRAS-mutated patients.
| (a) Clinical characteristics of KRAS-mutated patients | |
|---|---|
| Age at diagnosis (years) | |
| Median (Q1–Q3) | 67.5 (61–73) |
| Follow-up (months) | |
| Median (Q1–Q3) | 13.1 (10.1–15.4) |
| Gender | |
| Male | 31 (53.4%) |
| Female | 27 (46.6%) |
| Smoking | |
| No | 8 (13.8%) |
| Yes | 21 (36.2%) |
| former | 29 (50.0%) |
| PS | |
| 0 | 26 (44.8%) |
| 1 | 28 (48.3%) |
| 2 | 4 (6.9%) |
| Total | 58 |
| (b) Disease burden and treatment characteristics across lines | |
|---|---|
| Extra-thoracic sites | |
| No | 31 (42.5%) |
| 1 | 24 (32.9%) |
| >1 | 18 (24.7%) |
| Number of metastatic sites | |
| 0–1 | 38 (52.1%) |
| 2–4 | 35 (47.9%) |
| Bone/liver | |
| No | 47 (64.4%) |
| Bone | 9 (12.3%) |
| Liver | 9 (12.3%) |
| Both | 8 (11.0%) |
| Treatment lines | |
| 1 | 43 (58.9%) |
| >1 | 30 (41.1%) |
| Type of treatment | |
| Immunotherapy | 34 (46.6%) |
| Nivolumab | 12 (16.4%) |
| Pembrolizumab | 18 (24.7%) |
| Atezolizumab | 4 (5.5%) |
| Mono-chemotherapy | 14 (19.2%) |
| Docetaxel-Nintedanib | 2 (2.7%) |
| Docetaxel | 5 (6.9%) |
| Gemcitabine | 2 (2.7%) |
| Vinorelbine | 5 (6.9%) |
| Platinum-doublet | 25 (34.2%) |
| Platinum-pemetrexed | 17 (23.3%) |
| platinum-gemcitabine | 6 (8.2%) |
| carboplatinum-paclitaxel | 2 (2.7%) |
| Total | 73 |